The 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) was held recently in Brighton, UK. This report focuses on drug safety presentations made at the conference. Table 1 summarizes other relevant presentations not included in the following narrative.
Antidiabetic drugs in the spotlight

Cancer risk
A meta-analysis of four randomized controlled trials (RCTs) that looked at improving glycaemic control in type 2 diabetes mellitus (T2DM) was presented by Jeffrey Johnson (University of Alberta, Edmonton, AB, Canada). His group was aiming to find out whether the increased cancer risk seen in T2DM might be due to poor metabolic control. In four trials that reported cancer mortality (UKPDS 33, UKPDS 34, ACCORD and VADT) the risk estimate was not significantly different compared with controls. Three trials reporting cancer incidence (ADVANCE, PROactive and RECORD) showed similar results. While this study has limitations (i.e. it is a secondary analysis and was not a full systematic review), the author suggests that improving glycaemic control in T2DM patients does not reduce cancer risk.
In another presentation, Hui Zhang (Harvard School of Public Health, Boston, MA, USA) showed that a retrospective cohort study of electronic medical records from the UK General Practice Research Database (GPRD) did not find evidence that hypoglycaemic drugs are associated with an increased risk of cancer. Their study comprised 63,838 incident diabetic patients and 4632 cancer cases. Hazard ratios (HRs) for each additional year of use of rosiglitazone, pioglitazone, metformin, sulphonylurea and insulin were not significant.
These results are at odds with the putative protective effects of metformin demonstrated both in vitro [Memmott and Dennis, 2010] and in vivo [Jalving et al. 2010] .
Cardiovascular risk
Linda Levesque (McGill University, Montreal, QC, Canada) looked specifically at cardiovascular risk associated with metformin usage. Her group performed a nested casecontrol (NCC) analysis on a cohort of 42,775 adults who were treated with a hypoglycaemic drug from 1978 to 1999 (i.e. specifically to exclude thiazolidinedione usage). The study endpoints were first hospitalization for acute myocardial infarction (MI), death due to ischaemic heart disease (IHD) or first hospitalization for congestive heart failure (CHF). There were 4806 hospitalizations for acute MI and 5439 cardiac deaths. There was a significantly lower risk of MI with metformin compared with sulphonylurea usage (adjusted rate ratio [RR] 0.81; 95% confidence interval [CI] 0.690.95), especially as duration of therapy progressed. Dr Levesque commented that this reduction is on a par with that seen with statin drugs. Metformin had no effect on cardiovascular death, however. This study adds to the data supporting metformin for first-line use in T2DM.
MI, fractures and macular oedema have been documented with thiazolidinedione use in T2DM patients. Their safety profile has been examined by Elisabetta Poluzzi and colleagues (University of Bologna, Bologna, Italy) using the FDA Adverse Event Reporting Database (AERS). A case/noncase method was used to identify adverse drug reactions with thiazolidinediones A reporting odds ratio (OR) was used to ascertain risk compared to other antidiabetic drugs. The frequency of cardiovascular reactions, macular oedema and fractures were significantly higher with thiazolidinediones. In particular, the reporting OR for congestive cardiac failure was 6.11 (CI 5.68-6.56) versus 0.66 (CI 0.60-0.73).
Acute pancreatitis
Raymond Schlienger (Novartis, Basel, Switzerland) presented results of a cohort study (NCC) which looked at the risk of acute pancreatitis (AP) in T2DM associated with antidiabetic treatment. There were 419 AP patients selected from a starting group of 85,525 T2DM patients and 200,000 from the general population taken from The Health Improvement Network (THIN) database. The results showed that T2DM causes a moderate increase in AP risk (relative AP risk OR 1.35; CI 0.981.86). Analysis of drug use showed that insulin treatment (adjusted OR 0.35; CI 0.200.61) and long-term metformin (adjusted OR 0.49; CI 0.270.89) use seems to reduce, but long-term sulphonylurea (adjusted OR 1.69; CI 1.032.78) use increased, AP risk.
There have been spontaneous case reports of AP with the new incretin mimetic, exenatide, but a retrospective cohort study found no association. Made Wenten (Amylin Pharmaceuticals, San Diego, CA, USA) gave results from a follow-up study using a large US health insurance claims database. Data on 24,000 patients taking exenatide and 450,000 taking other antidiabetic drugs were analysed using a discrete-time survival model with a study endpoint of first occurrence of AP. No excess risk of AP was found with exenatide (HR 0.95; CI 0.651.38).
Neuropsychiatric drugs
Cardiovascular risk
The results of a NCC study, which sought to determine the risk of heart failure (HF) in a cohort of patients with Parkinson's disease, were presented by Dr G Trifiro (Erasmus Medical Centre, Rotterdam, The Netherlands). The cohort was taken from four different European databases and consisted of 10,790 new users of dopamine agonists (DAs) and 14,669 new users of levodopa where follow up revealed 518 incident cases of HF. There was no difference in HF risk with ergot DAs and levodopa; however, pramipexole was associated with increased risk (OR 1.49; CI 1.082.05). Although there may be a biological cause for a differential effect among various DAs, Dr Trifiro added that detection bias and residual confounding could not be ruled out.
In another study, health databases in Quebec, Canada, were searched to identify a population cohort of over 71,000 older adults who had initiated antidepressant therapy between 1997 and 2004. NCC analysis examined the primary endpoint of first hospitalization for acute MI or cardiac death due to IHD. Linda Levesque (Queen's University, Kingston, Canada) stated that their analysis showed venlafaxine users were at a significantly lower risk of MI or death compared with those who had taken other antidepressants (adjusted RR 0.80; CI 0.660.97) and this was even more pronounced among patients with established cardiovascular disease. No benefit with selective serotonin reuptake inhibitors (SSRIs) was shown, although patients with a history of previous MI may show benefit. Dr Levesque postulated that venlafaxine's beneficial effect may be due to prevention of platelet aggregation, and that RCTs are warranted to confirm these findings.
Annalisa Rubino (Florence University, Florence, Italy) reported results of her group's NCC study of the THIN database, where they analysed the incident rate of cardiac valvulopathy among patients who had received serotoninergic drugs between 1990 and 2008. The calculation of ORs showed there was no evidence that his group of drugs caused cardiac valvulopathy.
Several antipsychotic drugs have been associated with sudden cardiac death (CD) and ventricular arrhythmia (VA). Medicaid data from five large US states was analysed by Charles Leonard and coworkers (University of Pennsylvania School of Medicine, Philadelphia, PA, USA) for new antipsychotic users (aged 3075 years from 1999 to 2003) and outcome was determined by emergency department visit for CD/VA with olanzapine used as the reference group. The adjusted HRs compared with olanzapine were 2.06 for chlorpromazine, 1.72 for haloperidol, and 0.73 for quetiapinerisperidone and perphenazine were close to unity. A subanalysis of first-prescription exposures increased the HRs for chlorpromazine and haloperidol. Dr Leonard commented that these results are consistent with the Arizona Center for Education and Research on Therapeutics which lists chlorpromazine and haloperidol (as well as mesoridazine, mimozide and thioridazine) as 'high risk' for torsades de pointes.
Krista Huybrechts (Boston University School of Public Health, Boston, MA, USA) and colleagues conducted a cohort study of almost 11,000 patients aged 65 years or older who were given psychotropic medications shortly after being admitted to nursing homes in British Columbia (between 1996 and 2006) . They looked at four measures: risk of death and hospitalization for three major medical events (femur fracture, pneumonia and HF). Proportional hazard models looking at risk within 180 days of treatment initiation showed that patients on conventional antipsychotic medicines or antidepressants had an increased risk of death (HR 1.47, CI 1.141.91 and HR 1.20, CI 0.961.50, respectively) . A similar increased risk of femur fracture was also observed in both drug groups. Patients receiving benzodiazepines had an increased risk of death (HR 1.28, CI 1.041.58) and HF (HR 1.54, CI 0.892.67) . Dr Huybrechts concluded that conventional antipsychotic medications, antidepressants and benzodiazepines appear to have at least the same magnitude of risk for adverse health outcomes as typical antipsychotic medications.
Other risks
Joshua Gagne (Harvard Medical School, Boston, MA, USA) presented results of a case-crossover study, which looked at the risk of seizure-related events (SREs) following refilling of anti-epileptic drugs (AEDs) and whether switching from branded to generic products carried an increased risk. They found that refilling an AED prescription with the same brand or generic produced a 2.3-fold increased risk of SREs. Switching to a different brand/generic produced only a small increase in risk (adjusted OR 1.19, CI 0.353.99) , which Dr Gagne said was a much smaller effect than has been reported in previous studies.
The increased risk of suicide and mortality associated with anticonvulsant drugs was investigated by Elisabeth Patorno and colleagues (Harvard Medical School, Boston, MA, USA) in a cohort study that included 297,620 new episodes of treatment with an anticonvulsant. Outcomes were suicide attempts, completed suicides and violent deaths. Compared with topiramate (reference drug), attempted/completed suicides were increased with gabapentin (HR 1.42; CI 1.111.80), lamotrigine (HR 1.84; CI 1.432.37), oxcarbazepine (HR 2.07; CI 1.522.80), tiagabine (HR 2.41; CI 1.653.52) and valproate (HR 1.65; CI 1.252.19) and the risk was especially high within the first 30 days of treatment. In a secondary analysis, gabapentin showed increased risk compared with carbamazepine (reference drug) in both young and old patient groups, patients with mood disorders and patients with epilepsy/seizure disorders.
The risk of fractures in patients with multiple sclerosis (MS) has been assessed by Frank de Vries and coworkers (Utrecht University, Utrecht, The Netherlands). Dr de Vries presented results of a population-based cohort study from the UK GPRD where 5565 MS patients were matched with 33,864 non-MS controls, although the adjusted HR for any fracture was 1.2 (CI 1.11.4) there was a threefold increased risk of hip fracture in MS patients. Fracture risk was significantly higher in patients who had taken oral glucocorticosteroids or antidepressants. The glucocorticosteroid risk increased with dose, i.e. 7.5 mg/day prednisolone equivalents produced a 2.3-fold increased risk compared with controls. Thus, fracture risk assessment is warranted in MS patients receiving oral steroids or antidepressants.
Cardiovascular risks with aspirin and NSAIDs Annica
Bergendal (Karolinska Institutet, Stockholm, Sweden) presented results from the TEHS population-based casecontrol study looking at risk of venous thromboembolism (VTE) with nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, paracetamol or statins. There were 1415 women (1864 years old) with a first-time VTE in the case group and these were matched by 1350 women from the Swedish population register. Use of NSAIDs, aspirin, paracetamol or statins during the last 3 months prior to a VTE event (or interview date in the control group) was recorded. Dr Bergendal presented preliminary results showing no VTE risk with any of the drugs. In fact, there is some suggestion of a mild protective effect with conventional dose aspirin and paracetamol, whilst frequent use low-dose aspirin shows significant protection (OR 0.50, CI 0.290.95). This may be confounded by the fact that frequent users of low-dose aspirin tend to be 'healthy users' which might bias results.
Many patients with intracerebral haemorrhage (ICH) may require antiplatelet medications, e.g. to prevent ICH ischaemic events; however, there is very little evidence or guidance about this as well as a perception that they are contraindicated. Robert Flynn and colleagues (University of Hertfordshire, Hatfield, UK) followed up a cohort of stroke patients with confirmed ICH from Tayside, Scotland. They looked at use of aspirin, dipyridamole or clopidogrel with the primary outcome being recurrent ICH. In his presentation, Dr Flynn stated that of 942 initial ICH events there were 417 patients who survived to follow up (total follow up of 1510 patient years). Of these, 120 received antiplatelet medications. Median time from discharge to first use was 14.8 months. There were 14 recurrent ICH. Interestingly, there were 29 cases of subsequent ischaemic stroke and 44 cases of subsequent ischaemic stroke or MI. HRs were not significant on any of these outcomes. Thus, antiplatelet medications had no significant impact on outcomes, which calls into question why they should be contraindicated in recurrent ICH. Dr Flynn concluded that their study rules out neither moderate harm or benefit associated with antiplatelet medicine prescribing following ICH. It should be borne in mind that these are very small numbers. Further studies are warranted to confirm these preliminary findings.
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